



Barristers and Solicitors/Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

August 24, 2001

Micheline Gravelle B.Sc., M.Sc. (Immunol.)  
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 09/551,151  
Our Reference: 10447-11

Commissioner of Patents  
& Trademarks  
Washington, D.C. 20231  
U.S.A

RECEIVED  
TECH CENTER 1600/2900  
02 NOV -5 PM 12:58

Dear Sirs:

**Re: Response to Office Action**  
**U.S. Patent Application No. 09/551,151**  
**Entitled: Ricin-Like Toxin Variants for Treatment of Cancer, Viral or**  
**Parasitic Infections**  
**Filed: April 14, 2000**  
**Applicant: Thor Borgford**  
**Examiner: Hope Robinson**  
**Group Art No.: 1653**

---

The present letter is filed in response to Office Action mailed July 2, 2001, enclosing a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

Please amend the application as follows:

**In the Abstract**

Please renumber the Abstract page 88 as page 137.

**In the Disclosure**

Please insert the enclosed Sequence Listing at pages 81 – 129.

**In the Claims**

Please renumber claim pages 81-87 currently of record as 130-136.

**REMARKS**

In order to comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, Applicants are submitting herewith (1) a Sequence Listing in paper form; (2) a Sequence Listing in computer readable form (a 3.5" floppy diskette) in the ASCII format and (3) a statement (set forth below) that the paper form and the computer readable form of the Sequence Listing are the same.